AKT2 is linked to metabolic re−programming and invasion (30), and AKT3 correlates with cancer growth, aggressiveness and chemoresistance in ovarian cancer (31), suggesting that each isoform may contribute uniquely to the cetrorelix response. Here, AKT3 is linked to ovarian cancer.